Variation in dermcidin expression in a range of primary human tumours and in hypoxic/oxidatively stressed human cell lines
- PMID: 18594538
- PMCID: PMC2453008
- DOI: 10.1038/sj.bjc.6604458
Variation in dermcidin expression in a range of primary human tumours and in hypoxic/oxidatively stressed human cell lines
Abstract
Dermcidin acts as a survival factor in a variety of cancer cell lines under hypoxia or oxidative stress. The aim of this study was to evaluate dermcidin expression in cell lines following simulation of tumour microenvironmental conditions and in a range of primary tumours. Tumour tissues were collected from patients with oesophageal (28 samples), gastric (20), pancreatic (five), bile duct (one) and prostatic (52) carcinomas as well as 30 benign tissue samples, for assessment of dermcidin mRNA levels using real-time PCR. Dermcidin expression was assessed in prostatic and pancreatic cancer cell lines, with and without induction of hypoxia or oxidative stress. Dermcidin mRNA expression was very low or absent in both unstressed and stressed prostate cell lines. None of the primary prostate tissue, benign or malignant, expressed dermcidin mRNA. Only two (4%) of the gastro-oesophageal cancer samples expressed moderate quantities of dermcidin mRNA. However, three (60%) of the pancreatic cancer samples and the single cholangiocarcinoma specimen had moderate/high levels of dermcidin expression. Of the two pancreatic cancer cell lines, one expressed dermcidin moderately but neither showed a response to hypoxia or oxidative stress. Expression of dermcidin in human primary tumours appears highly variable and is not induced substantially by hypoxia/oxidative stress in cell line model systems. The relationship of these findings to dermcidin protein levels and cell survival remains to be determined.
Figures


Similar articles
-
Dermcidin expression confers a survival advantage in prostate cancer cells subjected to oxidative stress or hypoxia.Prostate. 2007 Sep 1;67(12):1308-17. doi: 10.1002/pros.20618. Prostate. 2007. PMID: 17626247
-
Hypoxic regulation of PFKFB-3 and PFKFB-4 gene expression in gastric and pancreatic cancer cell lines and expression of PFKFB genes in gastric cancers.Acta Biochim Pol. 2006;53(4):789-99. Epub 2006 Dec 4. Acta Biochim Pol. 2006. PMID: 17143338
-
Dermcidin as a novel binding protein of lncRNA STCAT3 and its effect on prognosis in gastric cancer.Oncol Rep. 2018 Nov;40(5):2854-2863. doi: 10.3892/or.2018.6673. Epub 2018 Aug 24. Oncol Rep. 2018. PMID: 30226544
-
The dermcidin gene in cancer: role in cachexia, carcinogenesis and tumour cell survival.Curr Opin Clin Nutr Metab Care. 2008 May;11(3):208-13. doi: 10.1097/MCO.0b013e3282fb7b8d. Curr Opin Clin Nutr Metab Care. 2008. PMID: 18403914 Review.
-
Mechanisms of regulation of PFKFB expression in pancreatic and gastric cancer cells.World J Gastroenterol. 2014 Oct 14;20(38):13705-17. doi: 10.3748/wjg.v20.i38.13705. World J Gastroenterol. 2014. PMID: 25320508 Free PMC article. Review.
Cited by
-
Binding of Y-P30 to syndecan 2/3 regulates the nuclear localization of CASK.PLoS One. 2014 Feb 3;9(2):e85924. doi: 10.1371/journal.pone.0085924. eCollection 2014. PLoS One. 2014. PMID: 24498267 Free PMC article.
-
Analysis of Y-P30/Dermcidin expression and properties of the Y-P30 peptide.BMC Res Notes. 2014 Jun 26;7:400. doi: 10.1186/1756-0500-7-400. BMC Res Notes. 2014. PMID: 24969620 Free PMC article.
-
Dermcidin exerts its oncogenic effects in breast cancer via modulation of ERBB signaling.BMC Cancer. 2015 Feb 19;15:70. doi: 10.1186/s12885-015-1022-6. BMC Cancer. 2015. PMID: 25879571 Free PMC article.
-
Chemical Barrier Proteins in Human Body Fluids.Biomedicines. 2022 Jun 22;10(7):1472. doi: 10.3390/biomedicines10071472. Biomedicines. 2022. PMID: 35884778 Free PMC article. Review.
-
A nine-gene signature predicting clinical outcome in cutaneous melanoma.J Cancer Res Clin Oncol. 2013 Feb;139(2):249-58. doi: 10.1007/s00432-012-1322-z. Epub 2012 Oct 9. J Cancer Res Clin Oncol. 2013. PMID: 23052696 Free PMC article.
References
-
- Akerblom IE, Murry LE (1998) Human cachexia associated protein. Incyte Pharmaceuticals Inc.: Palo Alto, CA [628413(5,834,192)]
-
- Bevilacqua A, Ceriani MC, Capaccioli S, Nicolin A (2003) Post-transcriptional regulation of gene expression by degradation of messenger RNAs. J Cell Physiol 195: 356–372 - PubMed
-
- Brown JM, Wilson WR (2004) Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 4: 437–447 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical